Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages

Mizanur Rahman, Akiko Kukita, Toshio Kukita, Takeo Shobuike, Takahiro Nakamura, Osamu Kohashi

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer therapeutic agents and have been demonstrated to induce differentiation in some myeloid leukemia cell lines. In this study, we show that HDAC inhibitors have a novel action on osteoclast differentiation. The effect of 2 HDAC inhibitors, trichostatin A (TSA) and sodium butyrate (NaB), on osteoclastogenesis was investigated using rat and mouse bone marrow cultures and a murine macrophage cell line RAW264. Both TSA and NaB inhibited the formation of preosteoclast-like cells (POCs) and multinucleated osteoclast-like cells (MNCs) in rat bone marrow culture. By reverse transcription-polymerase chain reaction analysis, TSA reduced osteoclast-specific mRNA expression of cathepsin K and calcitonin receptor (CTR). In contrast, TSA and NaB did not affect the formation of bone marrow macrophages (BMMs) induced by macrophage colony-stimulating factor as examined by nonspecific esterase staining. Fluorescence-activated cell sorting analysis showed that TSA did not affect the surface expression of macrophage markers for CD11b and F4/80 of BMMs. TSA and NaB also inhibited osteoclast formation and osteoclast-specific MRNA expression in RAW264 cells stimulated with receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL). Transient transfection assay revealed that TSA and NaB dose dependently reduced the sRANKL-stimulated or tumor necrosis factor α (TNF-α)-stimulated transactivation of NF-κB-dependent reporter genes. The treatment of RAW264 cells with TSA and NaB inhibited TNF-α-induced nuclear translocation of NF-κB and sRANKL-induced activation of p38 mitogen-activated protein kinase (MAPK) signals. These data suggest that both TSA and NaB exert their inhibitory effects by modulating osteoclast-specific signals and that HDAC activity regulates the process of osteoclastogenesis.

Original languageEnglish
Pages (from-to)3451-3459
Number of pages9
JournalBlood
Volume101
Issue number9
DOIs
Publication statusPublished - May 1 2003

Fingerprint

trichostatin A
Histone Deacetylase Inhibitors
Butyric Acid
Macrophages
Osteoclasts
Bone
Bone Marrow
Cells
Osteogenesis
Rats
Calcitonin Receptors
Cathepsin K
Cell Line
Carboxylesterase
Myeloid Leukemia
Macrophage Colony-Stimulating Factor
Histone Deacetylases
Polymerase chain reaction
p38 Mitogen-Activated Protein Kinases
Myeloid Cells

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. / Rahman, Mizanur; Kukita, Akiko; Kukita, Toshio; Shobuike, Takeo; Nakamura, Takahiro; Kohashi, Osamu.

In: Blood, Vol. 101, No. 9, 01.05.2003, p. 3451-3459.

Research output: Contribution to journalArticle

Rahman, Mizanur ; Kukita, Akiko ; Kukita, Toshio ; Shobuike, Takeo ; Nakamura, Takahiro ; Kohashi, Osamu. / Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. In: Blood. 2003 ; Vol. 101, No. 9. pp. 3451-3459.
@article{647ee4a696ae44cba959eff207778c14,
title = "Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages",
abstract = "Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer therapeutic agents and have been demonstrated to induce differentiation in some myeloid leukemia cell lines. In this study, we show that HDAC inhibitors have a novel action on osteoclast differentiation. The effect of 2 HDAC inhibitors, trichostatin A (TSA) and sodium butyrate (NaB), on osteoclastogenesis was investigated using rat and mouse bone marrow cultures and a murine macrophage cell line RAW264. Both TSA and NaB inhibited the formation of preosteoclast-like cells (POCs) and multinucleated osteoclast-like cells (MNCs) in rat bone marrow culture. By reverse transcription-polymerase chain reaction analysis, TSA reduced osteoclast-specific mRNA expression of cathepsin K and calcitonin receptor (CTR). In contrast, TSA and NaB did not affect the formation of bone marrow macrophages (BMMs) induced by macrophage colony-stimulating factor as examined by nonspecific esterase staining. Fluorescence-activated cell sorting analysis showed that TSA did not affect the surface expression of macrophage markers for CD11b and F4/80 of BMMs. TSA and NaB also inhibited osteoclast formation and osteoclast-specific MRNA expression in RAW264 cells stimulated with receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL). Transient transfection assay revealed that TSA and NaB dose dependently reduced the sRANKL-stimulated or tumor necrosis factor α (TNF-α)-stimulated transactivation of NF-κB-dependent reporter genes. The treatment of RAW264 cells with TSA and NaB inhibited TNF-α-induced nuclear translocation of NF-κB and sRANKL-induced activation of p38 mitogen-activated protein kinase (MAPK) signals. These data suggest that both TSA and NaB exert their inhibitory effects by modulating osteoclast-specific signals and that HDAC activity regulates the process of osteoclastogenesis.",
author = "Mizanur Rahman and Akiko Kukita and Toshio Kukita and Takeo Shobuike and Takahiro Nakamura and Osamu Kohashi",
year = "2003",
month = "5",
day = "1",
doi = "10.1182/blood-2002-08-2622",
language = "English",
volume = "101",
pages = "3451--3459",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages

AU - Rahman, Mizanur

AU - Kukita, Akiko

AU - Kukita, Toshio

AU - Shobuike, Takeo

AU - Nakamura, Takahiro

AU - Kohashi, Osamu

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer therapeutic agents and have been demonstrated to induce differentiation in some myeloid leukemia cell lines. In this study, we show that HDAC inhibitors have a novel action on osteoclast differentiation. The effect of 2 HDAC inhibitors, trichostatin A (TSA) and sodium butyrate (NaB), on osteoclastogenesis was investigated using rat and mouse bone marrow cultures and a murine macrophage cell line RAW264. Both TSA and NaB inhibited the formation of preosteoclast-like cells (POCs) and multinucleated osteoclast-like cells (MNCs) in rat bone marrow culture. By reverse transcription-polymerase chain reaction analysis, TSA reduced osteoclast-specific mRNA expression of cathepsin K and calcitonin receptor (CTR). In contrast, TSA and NaB did not affect the formation of bone marrow macrophages (BMMs) induced by macrophage colony-stimulating factor as examined by nonspecific esterase staining. Fluorescence-activated cell sorting analysis showed that TSA did not affect the surface expression of macrophage markers for CD11b and F4/80 of BMMs. TSA and NaB also inhibited osteoclast formation and osteoclast-specific MRNA expression in RAW264 cells stimulated with receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL). Transient transfection assay revealed that TSA and NaB dose dependently reduced the sRANKL-stimulated or tumor necrosis factor α (TNF-α)-stimulated transactivation of NF-κB-dependent reporter genes. The treatment of RAW264 cells with TSA and NaB inhibited TNF-α-induced nuclear translocation of NF-κB and sRANKL-induced activation of p38 mitogen-activated protein kinase (MAPK) signals. These data suggest that both TSA and NaB exert their inhibitory effects by modulating osteoclast-specific signals and that HDAC activity regulates the process of osteoclastogenesis.

AB - Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer therapeutic agents and have been demonstrated to induce differentiation in some myeloid leukemia cell lines. In this study, we show that HDAC inhibitors have a novel action on osteoclast differentiation. The effect of 2 HDAC inhibitors, trichostatin A (TSA) and sodium butyrate (NaB), on osteoclastogenesis was investigated using rat and mouse bone marrow cultures and a murine macrophage cell line RAW264. Both TSA and NaB inhibited the formation of preosteoclast-like cells (POCs) and multinucleated osteoclast-like cells (MNCs) in rat bone marrow culture. By reverse transcription-polymerase chain reaction analysis, TSA reduced osteoclast-specific mRNA expression of cathepsin K and calcitonin receptor (CTR). In contrast, TSA and NaB did not affect the formation of bone marrow macrophages (BMMs) induced by macrophage colony-stimulating factor as examined by nonspecific esterase staining. Fluorescence-activated cell sorting analysis showed that TSA did not affect the surface expression of macrophage markers for CD11b and F4/80 of BMMs. TSA and NaB also inhibited osteoclast formation and osteoclast-specific MRNA expression in RAW264 cells stimulated with receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL). Transient transfection assay revealed that TSA and NaB dose dependently reduced the sRANKL-stimulated or tumor necrosis factor α (TNF-α)-stimulated transactivation of NF-κB-dependent reporter genes. The treatment of RAW264 cells with TSA and NaB inhibited TNF-α-induced nuclear translocation of NF-κB and sRANKL-induced activation of p38 mitogen-activated protein kinase (MAPK) signals. These data suggest that both TSA and NaB exert their inhibitory effects by modulating osteoclast-specific signals and that HDAC activity regulates the process of osteoclastogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0038542837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038542837&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-08-2622

DO - 10.1182/blood-2002-08-2622

M3 - Article

C2 - 12511413

AN - SCOPUS:0038542837

VL - 101

SP - 3451

EP - 3459

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -